Crossref
EE58 ECONOMIC BURDEN OF RECURRENCE AFTER TRIMODAL THERAPY FOR BLADDER CANCER
Value in Health · 2026-06 · 29 (6) · S73-S74
DOI: 10.1016/j.jval.2026.03.353 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Ronac Mamtani und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Mamtani, R., Raut, M., Yapici, H., Jiao, W., Su, F., Davies, A., Lai, J. Y., Li, H., & Davis, N. (2026). EE58 ECONOMIC BURDEN OF RECURRENCE AFTER TRIMODAL THERAPY FOR BLADDER CANCER. Value in Health, 29(6), S73-S74. https://doi.org/10.1016/j.jval.2026.03.353
Vancouver
Mamtani R, Raut M, Yapici H, Jiao W, Su F, Davies A, et al. EE58 ECONOMIC BURDEN OF RECURRENCE AFTER TRIMODAL THERAPY FOR BLADDER CANCER. Value in Health. 2026;29(6):S73-S74. doi:10.1016/j.jval.2026.03.353
BibTeX
@article{Mamtani2026,
author = {Mamtani, Ronac and Raut, Monika and Yapici, Hal and Jiao, Weiqi and Su, Frank and Davies, Annabelle and Lai, Joyce Y. and Li, Haojie and Davis, Nancy},
title = {EE58 ECONOMIC BURDEN OF RECURRENCE AFTER TRIMODAL THERAPY FOR BLADDER CANCER},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {6},
pages = {S73--S74},
doi = {10.1016/j.jval.2026.03.353}
}
EUVIMED